Kidney Cancer Drugs Global Market Report 2021 - By Type (Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)), By Product (Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin)), By End Users (Hospitals, Clinics, Research Center), COVID-19 Impact And Recovery

aboutimg
Purchase Options
Request Sample
Request For Discount
FAQ
Infoimg

Starting Price : $5000.00 | Pages : 175 | Published : March 2021 | SKU CODE : 7219 | Delivery Time: 2-3 business days | Format :


Description Table Of Contents Tables & Figures Market Insights Related Reports

The kidney cancer drugs market consists of sales of kidney cancer drugs. It includes immunotherapy, chemotherapy and targeted therapy.

The market covered in the kidney cancer drugs market report is segmented by type into renal cell carcinoma (RCC), transitional cell carcinoma (TCC) or urothelial cell carcinoma (UCC); by product into nexavar (sorafenib), sutent (sunitinib), afinitor (everolimus), votrient (pazopanib), avastin (bevacizumab), inlyta (axitinib), torisel (temsirolimus), proleukin (aldesleukin), others; by end users into hospitals, clinics, research center, others.

The global kidney cancer drugs market is expected to decline from $3.3 billion in 2020 to $3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The slow decline is mainly due to the outbreak of COVID-19 that has led to deferment of immunocompromised treatments. The kidney cancer drugs market is expected to reach $3.6 billion in 2025 at a CAGR of 2.3%.

Rise in incidence of renal cancer acts as one of the major drivers of the kidney cancer drugs market. Change in lifestyle of people, consumption of tobacco and unhealthy diet are some factors which contribute to the growth of these renal cancer cells. According to American Cancer Society Report, an estimated 73,750 new cases of kidney (renal) cancer were diagnosed in the US in 2020. Thus, driving the growth of the kidney cancer drugs market.

Increasing use of biologics and targeted therapies acts as a restraint for the kidney cancer drugs market. When kidney cancer is spread to other organs, targeted therapies are used to control kidney cancer where chemical drugs are ineffective. Also, targeted drugs are used post kidney cancer surgery to prevent re-occurrence of kidney cancer. Conventional chemical drugs cannot be used in the same way. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials. In a study conducted by Pfizer, using targeted therapy had more chances of tumor shrinkage than using chemical drugs. Targeted drug, axitinib and Pembrolizumab are being used to treat stage IV kidney cancer which specially attacks the spreading points of cancer. Thus, pharmaceutical industry is embracing the targeted therapies because of the above-mentioned benefits. Therefore, hindering the growth of the kidney cancer drugs market.

Use of combination therapy is trending in the kidney (renal) cancer drugs market. Combination therapy combines the effects of various drugs thereby reducing the likelihood of cancer resistant cells from developing. The improved understanding about renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood are combined with inhibitors of mammalian target of rapamycin (mTor), which helps promote cellular biogenesis. According to a study conducted by National cancer institute (NIH) in 2019, the combination treatment leads to better outcomes in the patients suffering from advanced kidney cancer. In April 2019, Merck attained food and drug administration (FDA) approval to combine their drug Pembrolizumab, which enhances the patients’ immune system along with Pfizer’s drug Axitinib, which prevents the spread of renal cancer, this combination of drugs can help increase the pace of the patients’ recovery in advanced kidney cancer.

The kidney cancer drugs market is governed by regulatory framework of agencies such as Food and Administration Agency (FDA) and American Society of Clinical Oncology (ASCO). FDA's recommendation for kidney cancer drugs industry in the form of guidelines are mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312 that contains sub-parts from sub part 'A' to sub part 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening and illnesses such as kidney cancer. The sub part 'E' also includes guidelines for the monitoring and evaluation of clinical trials of kidney cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in kidney cancer drugs industry are required to abide to the regulations under FDA.

In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company which would address the needs of patients with cancer, inflammatory and immunologic disease and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA.

Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis, Inc., and F. Hoffmann-La Roche AG.

The regions covered in the kidney cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global kidney cancer drugs market is segmented -

1) By Type: Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)

2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Others

3) By End Users: Hospitals, Clinics, Research Center, Others

    Table Of Contents

    1. Executive Summary

    2. Kidney Cancer Drugs Market Characteristics

    3. Kidney Cancer Drugs Market Trends And Strategies

    4. Impact Of COVID-19 On Kidney Cancer Drugs

    5. Kidney Cancer Drugs Market Size And Growth

    5.1. Global Kidney Cancer Drugs Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Kidney Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Kidney Cancer Drugs Market Segmentation

    6.1. Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Renal Cell Carcinoma (RCC)

    Transitional Cell Carcinoma (TCC) or Urothelial cell carcinoma (UCC)

    6.2. Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Nexavar (Sorafenib)

    Sutent (Sunitinib)

    Afinitor (Everolimus)

    Votrient (Pazopanib)

    Avastin (Bevacizumab)

    Inlyta (Axitinib)

    Torisel (Temsirolimus)

    Proleukin (Aldesleukin)

    Others

    6.3. Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospitals

    Clinics

    Research Center

    Others

    7. Kidney Cancer Drugs Market Regional And Country Analysis

    7.1. Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Kidney Cancer Drugs Market

    8.1. Asia-Pacific Kidney Cancer Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.3. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.4. Asia-Pacific Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Kidney Cancer Drugs Market

    9.1. China Kidney Cancer Drugs Market Overview

    9.2. China Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.3. China Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.4. China Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Kidney Cancer Drugs Market

    10.1. India Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.2. India Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.3. India Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Kidney Cancer Drugs Market

    11.1. Japan Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.2. Japan Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.3. Japan Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Kidney Cancer Drugs Market

    12.1. Australia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.2. Australia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.3. Australia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Kidney Cancer Drugs Market

    13.1. Indonesia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.2. Indonesia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.3. Indonesia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Kidney Cancer Drugs Market

    14.1. South Korea Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.2. South Korea Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.3. South Korea Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Kidney Cancer Drugs Market

    15.1. Western Europe Kidney Cancer Drugs Market Overview

    15.2. Western Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.3. Western Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.4. Western Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Kidney Cancer Drugs Market

    16.1. UK Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.2. UK Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.3. UK Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Kidney Cancer Drugs Market

    17.1. Germany Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.2. Germany Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.3. Germany Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Kidney Cancer Drugs Market

    18.5. France Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.6. France Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.7. France Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Kidney Cancer Drugs Market

    19.1. Eastern Europe Kidney Cancer Drugs Market Overview

    19.2. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.3. Eastern Europe Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.4. Eastern Europe Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Kidney Cancer Drugs Market

    20.1. Russia Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.2. Russia Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.3. Russia Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Kidney Cancer Drugs Market

    21.1. North America Kidney Cancer Drugs Market Overview

    21.2. North America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.3. North America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.4. North America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Kidney Cancer Drugs Market

    22.1. USA Kidney Cancer Drugs Market Overview

    22.2. USA Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.3. USA Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.4. USA Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Kidney Cancer Drugs Market

    23.1. South America Kidney Cancer Drugs Market Overview

    23.2. South America Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.3. South America Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.4. South America Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Kidney Cancer Drugs Market

    24.1. Brazil Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.2. Brazil Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.3. Brazil Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Kidney Cancer Drugs Market

    25.1. Middle East Kidney Cancer Drugs Market Overview

    25.2. Middle East Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.3. Middle East Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.4. Middle East Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Kidney Cancer Drugs Market

    26.1. Africa Kidney Cancer Drugs Market Overview

    26.2. Africa Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.3. Africa Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.4. Africa Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Kidney Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Kidney Cancer Drugs Market Competitive Landscape

    27.2. Kidney Cancer Drugs Market Company Profiles

    27.2.1. Bayer AG

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Pfizer Inc

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Novartis International AG

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Exelixis, Inc

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. F. Hoffmann-La Roche Ag

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Kidney Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Kidney Cancer Drugs Market

    30. Kidney Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 27: South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 28: South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 29: Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 30: Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 31: Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 32: UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 33: UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 34: UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 35: Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 36: Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 37: Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 38: France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 39: France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 40: France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 41: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 42: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 43: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 44: Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 45: Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 46: Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 47: North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 48: North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 49: North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 50: USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 51: USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 52: USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 53: South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 54: South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 55: South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 56: Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 57: Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 58: Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 59: Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 60: Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 61: Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 62: Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 63: Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 64: Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 65: Bayer AG Financial Performance
  • Table 66: Pfizer Inc Financial Performance
  • Table 67: Novartis International AG Financial Performance
  • Table 68: Exelixis, Inc Financial Performance
  • Table 69: F. Hoffmann-La Roche Ag Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Kidney Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Global Kidney Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: Asia-Pacific, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: China, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: China, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: China, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: India, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: India, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: India, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Japan, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Japan, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Japan, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: Australia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: Australia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: Australia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Indonesia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: Indonesia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: Indonesia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: South Korea, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 27: South Korea, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 28: South Korea, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 29: Western Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 30: Western Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 31: Western Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 32: UK, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 33: UK, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 34: UK, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 35: Germany, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 36: Germany, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 37: Germany, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 38: France, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 39: France, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 40: France, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 41: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 42: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 43: Eastern Europe, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 44: Russia, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 45: Russia, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 46: Russia, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 47: North America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 48: North America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 49: North America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 50: USA, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 51: USA, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 52: USA, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 53: South America, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 54: South America, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 55: South America, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 56: Brazil, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 57: Brazil, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 58: Brazil, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 59: Middle East, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 60: Middle East, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 61: Middle East, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 62: Africa, Kidney Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 63: Africa, Kidney Cancer Drugs Market, Segmentation By Product, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 64: Africa, Kidney Cancer Drugs Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 65: Bayer AG Financial Performance
  • Figure 66: Pfizer Inc Financial Performance
  • Figure 67: Novartis International AG Financial Performance
  • Figure 68: Exelixis, Inc Financial Performance
  • Figure 69: F. Hoffmann-La Roche Ag Financial Performance
Global Anti-Infective Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Cell and Gene Therapy Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Pharmaceutical Drugs And Biologics Logistics Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Pharmaceutical Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Microbiome Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global G-CSF (Granulocyte Colony Stimulating Factors) Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Global Therapeutic Proteins Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Read More
Cancer Diagnostics Global Market Report 2021 - By Products (Companion Diagnostics, Molecular Diagnostics), By End-User (Cancer Research Institutes, Diagnostic Laboratories, Hospitals), By Method (Biopsy, Endoscopy, Tumor Biomarker Tests, Imaging), By Application (Cervical Cancer, Breast Cancer, Liver Cancer, Blood Cancer, Kidney Cancer, Colorectal Cancer, Pancreatic Cancer, Ovarian Cancer, Melanoma), COVID-19 Growth And Change
View Report
Antibody Drug Conjugates Global Market Report 2021 - By Type (Monoclonal Antibodies, Linker, Drug/Toxin), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), By Product (Adcertis, Kadcyla), By Technology (Immunogen Technology, Seattle Genetics Technology, Immunomedics Technology), By End User (Hospital, Clinics), COVID-19 Growth And Change
View Report
Conjugated Monoclonal Antibodies Global Market Report 2021 - By Drugs (Adcetris, Kadcyla), By Technology (Cleavable Linker, Non-cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour), COVID-19 Growth And Change
View Report
Monoclonal Antibodies (MAbS) Global Market Report 2021 - By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End Users (Hospitals, Private Clinics, Research Institute), COVID-19 Impact And Recovery
View Report
Oncology Devices Global Market Report 2021 - By Device Type (Brachytherapy Devices, Endoscopic Devices), By Therapy (Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radition Therapy), By End User (Hospitals, Cancer Research Institutes), COVID-19 Growth And Change
View Report
Urology Medical Lasers Global Market Report 2021 - By Laser Type (Holmium Laser System, Diode Laser System, Thulium Laser System), By Application (Benign Prostatic Hyperplasia (BPH), Urolithiasis, Non-Muscle-Invasive Bladder Cancer (NMIBC)), By End User (Hospital, Clinic), COVID-19 Growth And Change
View Report
Cervical Cancer Diagnostics Global Market Report 2021 - By Diagnostic Test (Pap Smear Test, HPV Test, Colposcopy, Biopsy and Endocervical Curettage), By End User (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centres, Diagnostic Centres), By Age Group (Below 21, Between 21 To 29, Between 30 To 65, Above 65), COVID-19 Growth And Change
View Report
Oncology Drugs Global Market Report 2021 - By Type (Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs), COVID-19 Impact And Recovery
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)